Application of inhibiting N4BP1 based on super enhancer in preparation of medicine for resisting human oral squamous cell carcinoma
By inhibiting the activity of N4BP1 super-enhancer and BRD4, and utilizing the inhibitory molecules of N4BP1 super-enhancer and BRD4 inhibitors, the problem of lack of targets in OSCC treatment was solved, and effective inhibition of oral squamous cell carcinoma cells was achieved.
Patent Information
- Application Number
- CN202411050546.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-15
AI Technical Summary
Current technologies lack effective targets to improve the survival rate and quality of life of patients with oral squamous cell carcinoma (OSCC), resulting in low treatment response and strong drug resistance in tumor cells.
By using inhibitory molecules of the N4BP1 superenhancer and BRD4 inhibitors, such as JQ1 and I-BET-762, the function of the superenhancer is inhibited to suppress the expression of N4BP1, thereby inhibiting tumor cell growth.
By inhibiting the expression of N4BP1, the proliferation of oral squamous cell carcinoma cells was significantly suppressed, providing a potential new approach for the treatment of OSCC.
Smart Images

Figure CN118957065A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of super enhancer-based inhibition of N4BP1 in the preparation of drugs against human oral squamous cell carcinoma. Background Art
[0002] Oral cancer is the most common cancer among head and neck cancers and the 11th most common malignancy in the world. Recent trends show that the incidence and mortality of oral cancer continue to rise. About 90% of oral cancer cases belong to oral squamous cell carcinoma (OSCC). Despite progress in multimodal treatment strategies combining targeted systemic therapy and immune checkpoint therapy on the basis of traditional treatment options (surgery, chemotherapy, therapy), the 5-year survival rate of OSCC patients has remained at around 50% without significant improvement. Low treatment responsiveness and tumor cell resistance are the main challenges currently faced. Therefore, it has become an urgent need to explore the pathogenesis of OSCC and find new potential targets to improve the survival and quality of life of OSCC patients. Summary of the invention
[0003] The purpose of the present invention is to solve the technical problem of lack of potential targets for OSCC in the prior art.
[0004] In order to achieve the above object, the present invention adopts the following technical solutions:
[0005] Application of super enhancer of N4BP1 in the preparation of drugs for treating oral squamous cell carcinoma with high expression of N4BP1.
[0006] Preferably, the drug comprises an inhibitory molecule that inhibits the N4BP1 super enhancer.
[0007] The present application also provides the use of super enhancer key protein BRD4 as a target in the preparation of a drug for treating oral squamous cell carcinoma with high expression of N4BP1.
[0008] Preferably, the drug contains an inhibitor of BRD4.
[0009] Preferably, the BRD4 inhibitor is a BET inhibitor.
[0010] Preferably, the drug inhibits N4BP1 by inhibiting the function of super enhancers, thereby inhibiting tumor cell growth.
[0011] The present application also provides a drug for treating oral phosphocarcinoma, including an inhibitor of BRD4.
[0012] Preferably, the drug comprises at least one of JQ1, I-BET-762 and dBET.
[0013] Super enhancers (SEs) are cis-acting elements with strong transcriptional activity and a wide range in the genome. This region is rich in highly dense histone modifications (H3K27ac, H3K4me1), major transcription factors and cofactors, and other transcriptional devices to drive the expression of cell identity genes. Studies have shown that super enhancers exist in a variety of tumor cells, and after activation, they can drive the high expression of oncogenes and promote the occurrence and development of tumors.
[0014] Through specific verification experiments, the present application found that in oral squamous cell carcinoma cells, N4BP1 is regulated by super enhancers, is in a high expression state, and promotes tumor proliferation. BRD4, as an epigenetic regulator of super enhancers, shows the same expression trend as N4BP1 in oral squamous cell carcinoma. After treatment with BET inhibitors, N4BP1 expression in tumor cells is downregulated, and cell proliferation is significantly inhibited. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a comparison diagram of the expression levels of N4BP1 in HNSCC and healthy control tissues in one embodiment of the present invention;
[0016] Figure 2 The figure shows that the expression level of N4BP1 in OSCC cancer tissue is higher than that in adjacent tissue in one embodiment of the present invention, wherein (A) the relative expression level of N4BP1 protein in OSCC cancer tissue and adjacent tissue is detected by immunohistochemistry; (B) the relative expression level of N4BP1 mRNA in OSCC cancer tissue and adjacent tissue is detected by RT-PCR. Wherein * indicates P<0.05.
[0017] Figure 3 The figure shows the verification of the increased expression of N4BP1 in OSCC cell lines in one embodiment of the present invention; (A) using Western Blot technology, the relative expression level of N4BP1 protein in normal human oral epithelial HOK cells and human oral squamous cell carcinoma cells (SCC9, CAL27) was compared and detected; (B) RT-PCR was used to detect the relative expression level of N4BP1 mRNA in HOK, SCC9 and CAL27 cells. Among them, *, indicates P < 0.05; **, indicates P < 0.01; ***, indicates P < 0.001.
[0018] Figure 4The figure shows the expression level of BRD4 in the cell line in one embodiment of the present invention, wherein (A) the relative expression level of BRD4 protein in human oral keratinocyte HOK cells and human tongue squamous cell carcinoma SCC9 and CAL27 cells was compared and detected by Western Blot technology; (B) the relative expression level of BRD4 mRNA in HOK, SCC9 and CAL27 cells was detected by RT-PCR. Among them, * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001.
[0019] Figure 5 Schematic diagram of the verification of down-regulation of N4BP1 expression in SCC9 and CAL27 tumor cells by BRD4 inhibitor in one embodiment of the present invention, wherein (A) RT-PCR detection of the relative expression level of N4BP1 mRNA in SCC9 and CAL27 cells under different concentrations of JQ1, I-BET-762 and dBET stimulation conditions; (B) Western Blot detection of the relative expression level of N4BP1 protein in SCC9 and CAL27 cells under different concentrations of JQ1, I-BET-762 and dBET stimulation conditions. Where *, indicates P < 0.05; **, indicates P < 0.01; ***, indicates P < 0.001.
[0020] Figure 6 This is a schematic diagram of the verification of the killing ability of BRD4 inhibitors on SCC9 and CAL27 tumor cells in one embodiment of the present invention, specifically, the proliferation of SCC9 and CAL27 cells under different concentrations of JQ1, I-BET-762 and dBET stimulation conditions is detected by CCK-8 method. Among them, *, indicates P < 0.05; **, indicates P < 0.01; ***, indicates P < 0.001. DETAILED DESCRIPTION
[0021] The present invention is further described in detail below in conjunction with specific embodiments.
[0022] The present application provides the use of a super enhancer of N4BP1 in the preparation of a drug for treating oral squamous cell carcinoma with high expression of N4BP1, wherein the drug contains an inhibitory molecule that inhibits the super enhancer of N4BP1.
[0023] This application also provides the use of super enhancer key protein BRD4 as a target in the preparation of drugs for treating oral squamous cell carcinoma;
[0024] In one embodiment, the drug comprises an inhibitor of BRD4, wherein the inhibitor comprises a BET inhibitor, and the drug inhibits N4BP1 by inhibiting the function of super enhancers, thereby inhibiting the growth of tumor cells.
[0025] The present application also provides a drug for treating oral phosphocarcinoma, including an inhibitor of BRD4.
[0026] In one embodiment, the drug comprises at least one of JQ1, I-BET-762, and dBET.
[0027] The following is an explanation of the above content in combination with specific verification experiments:
[0028] Example 1: Expression levels of N4BP1 in HNSCC and healthy control tissues
[0029] See also Figure 1 , N4BP1 was significantly elevated in head and neck squamous cell carcinoma samples through analysis of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset.
[0030] Example 2: Verification of up-regulated expression of N4BP1 in OSCC
[0031] In this application, immunohistochemistry ( Figure 2 A) and RT-PCR ( Figure 2 B) analyzed tissue samples of OSCC patients, and the results showed that the expression level of N4BP1 in OSCC cancer tissues was significantly higher than that in adjacent tissues; at the same time, the expression of N4BP1 in human oral squamous cell carcinoma cell lines and normal oral epithelial cells was determined in this application ( Figure 3 The above data showed that N4BP1 was significantly upregulated at the transcriptional level in OSCC.
[0032] Example 3: Exploring the causes of N4BP1 upregulation
[0033] Considering that the activation of super enhancers (SEs) is an important way for tumor cells to upregulate the expression of key genes, and BRD4 is an important epigenetic regulator that activates SEs, this application first detected the expression of BRD4 in tongue squamous cell carcinoma cells ( Figure 4 ),like Figure 4 As shown in the figure, BRD4 is highly expressed in SCC9 and CAL27. This result suggests that the high expression of N4BP1 in OSCC may be related to BRD4 and regulated by SEs.
[0034] Example 4: Verification of the effect of super enhancer inhibitors on the expression of N4BP1 in tumor cells:
[0035] In this application, three small molecule inhibitors, JQ1, I-BET-762 and dBET6, were used to inhibit the activity of BRD4. RT-PCR and Western Blot detected that the mRNA and protein levels of N4BP1 were significantly downregulated in oral squamous cell carcinoma cells treated with BRD4 inhibitors ( Figure 5), indicating that N4BP1 is affected by BRD4 and that administration of a BRD4 inhibitor blocked super-enhancer activation.
[0036] Example 5: Verification of the effect of super enhancer inhibitors on oral squamous cell carcinoma:
[0037] Super-enhancer inhibitors not only inhibited the expression of N4BP1, but also had a significant inhibitory effect on the proliferation of oral squamous cell carcinoma cells ( Figure 6 ). The above results show that in oral squamous cell carcinoma cells, the present application can inhibit N4BP1 by inhibiting the function of super enhancers, and on this basis inhibit tumor cell growth. Super enhancer inhibitors may have good application potential for oral squamous cell carcinoma with high expression of N4BP1.
[0038] The following are some of the experimental steps used in the above examples:
[0039] (1) Immunohistochemical staining
[0040] ① Antigen repair: Place the prepared tissue sections in a clean, oil-free pressure cooker, add an appropriate amount of citrate repair buffer to the pressure cooker, and ensure that the tissue sections are completely immersed in the repair solution. Make sure the lid of the pressure cooker is tightly closed. During the heating process, pay attention to the pressure indicator of the pressure cooker to ensure that it is within the appropriate range. After heating, open the lid of the pressure cooker, gently take out the tissue sections, gently rinse the tissue sections with PBS to remove the residual repair solution, and gently dry the surface moisture of the tissue sections with a paper towel.
[0041] ② Block endogenous enzymes: Place tissue slices in 3% H2O2, making sure the slices are completely immersed in the solution. Observe the reaction of the tissue slices under a microscope, record the changes in the slices, and incubate for 5-60 minutes, depending on the experimental requirements. Rinse the tissue slices with PBS to remove residual H2O2, and use absorbent paper to absorb the moisture around the tissue slices.
[0042] ③Primary antibody incubation: Select the corresponding primary antibody according to the experimental requirements and dilute it according to the manufacturer's recommended concentration.
[0043] Add enough antibody to the tissue. Place the tissue slices in a histochemical incubation box, add PBS to prevent over-drying during the incubation process, and incubate in a 4°C refrigerator overnight. After the incubation is completed, rinse the slices with PBS to remove the residual primary antibody, and use absorbent paper to dry the moisture around the slices.
[0044] ④ Secondary antibody incubation: Select appropriate secondary antibodies according to experimental requirements and dilute according to the manufacturer's recommended concentration. Add sufficient antibody to the tissue. Place the tissue sections in a histochemical incubation box and incubate at room temperature for 2 hours. DAB color development after incubation: Prepare DAB color development solution at a ratio of A solution: B solution = 1:20, add 50-100μL to the tissue, and observe the color change under a microscope. After the color development is stable, rinse the sections with PBS to remove the residual color development solution, and use absorbent paper to absorb the moisture around the sections.
[0045] ⑤ Re-staining and sealing: Immerse the slices in the hematoxylin stain solution again for 8-15 minutes, and rinse carefully with clean water to remove excess hematoxylin dye and floating color. Quickly place the slices in the differentiation solution and stay for a few seconds to 30 seconds to make the cell structure clearer. Rinse again with clean water to restore the slices to their natural blue color. Dehydrate the slices by placing them in 75% alcohol, 95% alcohol, and anhydrous ethanol for 30 seconds each. Place the slices in xylene for 1 minute of transparent treatment. Subsequently, use neutral gum to seal the transparent slices. Finally, place the sealed slices under a microscope for observation.
[0046] (2) Cell culture
[0047] The two oral squamous cell carcinoma cell lines (CCL9 and CAL27) required for the experiment were cultured in DMEM containing 10% fetal bovine serum, 1% streptomycin and penicillin in a constant temperature incubator at 5% CO2 and 37°C.
[0048] (3) Protein immunoblotting
[0049] Protein Extraction:
[0050] After the digested cells were washed with PBS, an appropriate amount of RIPA lysis buffer was added to ensure that the cells were fully lysed. The cells were shaken on ice for 45 minutes, centrifuged at 12000r / min and 4℃ for 15 minutes, and the supernatant was collected. 5× protein loading buffer was added, and the cells were boiled in a 105℃ metal bath for 5 minutes, or heated at 95℃ for 10 minutes.
[0051] Gel electrophoresis and protein immunodetection:
[0052] ① Electrophoresis: Put the prepared gel into the electrophoresis tank, add the electrophoresis solution and gently remove the comb, mix the protein sample with a pipette and add it to each well in turn. Turn on the electrophoresis tank power supply, set the starting voltage to 80V, and when the protein marker begins to separate clear bands in the separation gel, increase the voltage to 120V. If the protein marker is completely separated, or the bromophenol blue migrates to a specific position at the bottom of the gel (such as 1cm), the electrophoresis can be ended.
[0053] ② Transfer: Place the transfer clip in the water tray filled with transfer fluid. This clip usually has two sides, black and white, open with the black side facing down and the white side facing up. Place a sponge pad on the blackboard and filter paper on it, open the glass plate, let the gel fall onto the filter paper, and adjust the position of the gel to ensure that it does not dry. Take a 0.45μm PVDF membrane and put it in methanol to activate for 15 seconds (if the molecular weight is particularly small, a 0.22μm PVDF membrane can be used), then remove it and put it in water to deactivate, after wetting with transfer fluid, carefully place it on the gel, and gently rinse with transfer fluid to remove bubbles. Put the membrane, filter paper, and sponge pad in order, gently close the transfer clip, ensure that the sponge pad and filter paper are wetted with transfer fluid, and put the clip in the transfer tank according to the principle of black to black and red to white. Inject transfer fluid into the transfer tank, turn on the power, adjust the current to 300mA, and set the appropriate transfer time according to the molecular weight of the target protein. For a molecule of 1 kDa, this takes approximately 1 minute.
[0054] ③ Blocking: After the transfer is completed, the PVDF membrane needs to be taken out and placed in 5% skim milk and blocked on a shaker at room temperature for 2 hours to ensure that the milk is fully bound to all binding sites on the membrane, thereby minimizing the possibility of nonspecific binding.
[0055] ④ Antibody incubation: Select the corresponding primary antibody according to the experimental requirements, dilute the antibody according to the manufacturer's recommended concentration, then add a sufficient amount of diluted antibody to the PVDF membrane, and then incubate the membrane in a 4°C refrigerator overnight. After incubation, wash the membrane three times with 1×TBST washing solution for 5 minutes each time to remove residual primary antibody. Select the corresponding secondary antibody and dilute it with 5% skim milk at a ratio of 1:2000, and incubate at room temperature for 2 hours. After incubation, wash the membrane three times with 1×TBST washing solution for 20 minutes each time to remove residual secondary antibody.
[0056] ⑤ Development: ECL luminescent solution is composed of liquid A and liquid B, which need to be mixed in a 1:1 ratio. The key to this step is to ensure that the two liquids are mixed evenly and that they are used immediately after being prepared to avoid long-term storage causing the solution to become ineffective. Evenly drop the prepared ECL luminescent solution on the membrane and use a chemiluminometer to develop the membrane. The development time and number of sheets can be adjusted according to different protein antibodies.
[0057] (4) Real-time quantitative PCR (RT-PCR)
[0058] Extraction of total RNA from cells:
[0059] Digest the cells with trypsin to separate them from the dish, pipette the cells into an RNase-Free EP tube, centrifuge at 1000r / min for 5 minutes, discard the supernatant to collect the cell pellet. Add 1mL of Trizol reagent to the centrifuge tube and mix by blowing repeatedly. If RNA extraction cannot be performed in time, the cell pellet can be directly placed in a -80℃ freezer. Place the sample at room temperature for 5 minutes. To completely separate the nucleic acid-protein complex, add 200μL of chloroform, then shake vigorously for 15 seconds, and then let it stand at room temperature for 3 minutes. Then centrifuge at 12000r / min for 15 minutes at 4℃, so that the sample will be separated into three layers. Transfer the supernatant to a new RNase-Free EP tube, add an equal amount of isopropanol to precipitate RNA, and place it at room temperature for 10 minutes or in a -20℃ freezer for 1 hour. Centrifuge at 12000r / min for 10 minutes at 4°C. After centrifugation, a gelatinous precipitate will be seen on the side and bottom of the test tube. At this time, the supernatant needs to be carefully removed. Next, wash the RNA precipitate with 1mL of 75% ethanol, centrifuge again at 7500r / min for 5 minutes at 4°C, remove the supernatant, and repeat this step twice. Leave the dried RNA precipitate at room temperature for about 10-30 minutes, add 20-100μL of RNase-Free enzyme ultrapure water, pipette several times, place in a 55-60°C water bath for 10 minutes to dissolve the RNA, and store at -80°C.
[0060] Reverse transcription of RNA to cDNA
[0061] ① Take 8 tubes of RNase-Free and place them on ice. II Reverse Transcriptase Instructions Reverse transcription of RNA to synthesize cDNA.
[0062] Table 5 Reverse transcription reaction system
[0063]
[0064] ② Transfer the mixture to a PCR instrument and perform a reverse transcription reaction. The specific temperature settings are: 37°C for 15 minutes and 85°C for 5 seconds. After the reaction is completed, the product can be directly used for subsequent PCR reactions, or stored in a -20°C refrigerator for later use.
[0065] RT-PCR:
[0066] ① Dilute the cDNA product obtained by the above reversal 5 times, take 0.2μL of upstream primer, 0.2μL of downstream primer, 5μL of 5×SYBR Green, 2.6μL of RNase-Free ddH2O and 2μL of diluted cDNA product and add them to the 96-well plate. Put the 96-well plate with the sample into a low-speed centrifuge, centrifuge at 3500r / min for 3 minutes, and put the 96-well plate into the PCR instrument after centrifugation.
[0067] Table 6 PCR reaction conditions
[0068]
[0069] ②Use 2 -△△C Data analysis was performed using the T method.
[0070] Table 7 RT-PCR primers
[0071]
[0072] (5) CCK-8 method to detect the sensitivity of tumor cells to chemotherapy drugs
[0073] The digested cells were seeded in a 96-well plate at a density of 3,000 cells and cultured for 8 hours until the cells adhered to the wall. The complete culture medium containing the required concentration of chemotherapy drugs was replaced. According to the experimental design, the CCK8 kit was used to detect cell viability at different time points.
[0074] In summary, this application first discovered that the increased expression of N4BP1 in oral squamous cell carcinoma cells is regulated by a super enhancer, and clarified the sequence location of the super enhancer in the N4BP1 genome. Treatment of tumor cells with a BRD4 inhibitor resulted in downregulation of N4BP1 expression, which is a possible reason for inhibiting tumor proliferation.
Claims
1. Application of super enhancer of N4BP1 in the preparation of drugs for treating oral squamous cell carcinoma with high expression of N4BP1.
2. The use of the super enhancer of N4BP1 as a target in a drug for treating oral squamous cell carcinoma according to claim 1, characterized in that: The drug contains inhibitory molecules that inhibit N4BP1 super enhancer.
3. Application of super-enhancer key protein BRD4 as a target in the preparation of drugs for the treatment of oral squamous cell carcinoma with high expression of N4BP1.
4. The use of BRD4 as a target in the preparation of a drug for treating oral squamous cell carcinoma according to claim 3, characterized in that: The drug comprises an inhibitor of BRD4.
5. The use of BRD4 as a target in the preparation of a drug for treating oral squamous cell carcinoma according to claim 3, characterized in that: The BRD4 inhibitor is a BET inhibitor.
6. The use of BRD4 as a target in the preparation of a drug for treating oral squamous cell carcinoma according to claim 3, characterized in that: The drug inhibits N4BP1 by suppressing the function of super enhancers, thereby inhibiting tumor cell growth.
7. A drug for treating oral phosphorus cancer, characterized in that: Including inhibitors of BRD4.
8. A drug for treating oral phosphorus cancer according to claim 5, characterized in that: The drug includes at least one of JQ1, I-BET-762 and dBET.
